Skip to main content
SPARC - Logo
Innovations Inspired by life
Menu

Hamburger

  • Our Company
    • Who we are
    • History
    • Culture
    • Board of Directors
    • Leadership Team
  • OUR RESEARCH
    • Therapeutic focus
    • Delivery Technologies
    • Research Programs
    • R&D Pipeline
  • Our Medicines
    • Xelpros®
    • Elepsia® XR
  • Business Development
    • Strategy
    • Partner with us
  • Accreditations And Approvals
    • Good Laboratory Practice
  • Investors
    • Who we are
    • Financials
    • Annual reports
    • Presentations
    • Chairman's Speech
    • Committees of BOD's
    • Shareholding pattern
    • Announcements & Disclosures
    • Policies & Codes
    • Listing Information
    • Board of Directors
    • FAQ’s, Guide Book and Forms for Shareholders
    • Investors Contact
    • Go green
    • IEPF
  • Media
    • Press Releases
    • Presentations
  • Careers
    • Overview
    • Apply Now
  • Contact Us
Home » Oncology

Home page banner readmore links left menu

  • Home
    • Innovations Inspired by Life
    • Oncology
    • Neuro Degeneration
    • Ophthalmology
    • Dermatology

Oncology

oncology

 

Resistance to chemotherapy and molecularly targeted therapies are major challenges associated with current cancer research. The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific molecular targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death. With the increasing arsenal of anticancer agents, improving preclinical models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.

At SPARC, we are working on next generation small molecules to overcome resistance observed with existing drugs in Haematology, Breast Cancer, Lung Cancer and Prostate Cancer.

 

Our Company

  • Who we are
  • history
  • Culture
  • board of directors
  • Leadership team

Our Research

  • Therapeutic focus
  • Delivery Technologies
  • Research Programs
  • R&D Pipeline

Investor Relations

  • Financials
  • Announcements & Disclosures
  • Shareholding pattern
  • Listing Information

Quick Links

Quick Links

  • Business Development
  • Investors
  • Media
  • Careers

Social Connect

  • twitter
  • linkedin

Employee Portal »

Copyright © 2019. Sun Pharma Advanced Research Company Ltd. All rights reserved.
Terms of Use  |   Archival Policy   |   Sitemap
Site Credits